• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ: OBIO )

    5.020 +0.190 (+3.93%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 26,809
    Open 4.900
    Bid (Size) 4.810 (1)
    Ask (Size) 5.100 (2)
    Prev. Close 4.830
    Today's Range 4.710 - 5.020
    52wk Range 4.220 - 11.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024
    OBIO stock results show that Orchestra BioMed Hldgs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -42.82%
    -42.82%
    1 Month
    -24.85%
    -24.85%
    3 Month
    -29.49%
    -29.49%
    6 Month
    +1.41%
    +1.41%
    1 Year
    -42.43%
    -42.43%

    More News

    Read More
    Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
    From Precision Neuroscience
    Via GlobeNewswire
    Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed to Participate in Upcoming Investor Conferences
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    Top 4 Health Care Stocks That Should Keep You Up At Night
    Via Benzinga
    Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Shares of Orchestra BioMed Jumped Tuesday
    Via The Motley Fool
    Exposures Product Safety
    Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.